A share price of Clearside Biomedical Inc [CLSD] is currently trading at $1.80, up 10.43%. An important factor to consider is whether the stock is rising or falling in short-term value. The CLSD shares have gain 4.05% over the last week, with a monthly amount glided 38.46%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 18, March 2024, Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer. In a post published today on Yahoo Finance, Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on July 29, 2021, and set its price target to $10. On May 13, 2020, ROTH Capital initiated with a Buy rating and assigned a price target of $8 on the stock. Needham downgraded its rating to a Hold. Stifel downgraded its rating to a Hold. JP Morgan downgraded its rating to Underweight for this stock on November 05, 2018. In a note dated November 05, 2018, Cowen downgraded an Market Perform rating on this stock.
Clearside Biomedical Inc experienced fluctuations in its stock price throughout the past year between $0.65 and $2.12. Clearside Biomedical Inc [NASDAQ: CLSD] shares were valued at $1.80 at the most recent close of the market.
Analyzing the CLSD fundamentals
Trailing Twelve Months sales for Clearside Biomedical Inc [NASDAQ:CLSD] were 8.23M which represents 1822.73% growth. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -3.02%, Pretax Profit Margin comes in at -3.95%, and Net Profit Margin reading is -4.42%. To continue investigating profitability, this company’s Return on Assets is posted at -1.07, Equity is 4.68 and Total Capital is -0.91. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6867 points at the first support level, and at 1.5733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8567, and for the 2nd resistance point, it is at 1.9133.
Clearside Biomedical Inc [CLSD] reported earnings per share of -$0.08 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.09/share, meaning a difference of $0.01 and a surprise factor of 11.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.15 per share as compared to estimates of -$0.15 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Clearside Biomedical Inc [NASDAQ:CLSD] is 4.42. On the other hand, the Quick Ratio is 4.42, and the Cash Ratio is 4.24. Considering the valuation of this stock, the price to sales ratio is 16.34.
Transactions by insiders
Recent insider trading involved Chong Ngai Hang Victor, CHIEF MEDICAL OFFICER, that happened on Mar 20 ’24 when 30000.0 shares were purchased. 10% Owner, WHITMORE BRADFORD T completed a deal on Feb 07 ’24 to buy 0.44 million shares. Meanwhile, CEO LASEZKAY GEORGE M sold 18000.0 shares on Jan 19 ’24.
